About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

BostonGene Appoints Dr. Ferran Prat as Chief Commercial Officer

BostonGene, a leader in AI-driven molecular and immune profiling that accelerates drug development and personalizes patient care, is pleased to announce the appointment of Ferran Prat, PhD, JD, as the Company’s Chief Commercial Officer (CCO). In this role, Dr. Prat will oversee the Company’s commercial strategy, including sales, marketing and business development.

Dr. Prat is a performance-focused leader with extensive experience in business development across the healthcare, pharmaceutical and biotechnology industries, spanning licensing, sales, regulatory affairs, operations and program management.

Dr. Prat joins BostonGene from The University of Texas MD Anderson Cancer Center, where he served as Senior Vice President of Research Administration and Industry Relations, leading strategic collaborations with the biopharma industry to translate groundbreaking science into clinical impact. His leadership helped establish MD Anderson as a hub for industry partnerships and accelerated therapeutic development.

“We are excited to welcome Ferran to BostonGene,” said Andrew Feinberg, President and CEO of BostonGene. “Ferran brings a unique blend of scientific insight, business acumen and legal expertise, making him a valuable addition to our exceptional leadership team committed to transforming healthcare and drug development through AI. His proven track record of building impactful partnerships with leading pharmaceutical and biotech companies will be instrumental as we continue to expand our role in accelerating drug development.”

“BostonGene is redefining what is possible at the intersection of science, data and patient care,” said Dr. Ferran Prat. “Its multimodal, multiscale AI-driven platform generates powerful insights that accelerate therapeutic development and lead to better patient outcomes. As the industry increasingly focuses on personalized medicine and more strategic R&D investment, BostonGene is uniquely positioned to deliver real-world impact and drive meaningful transformation across healthcare and biopharma while saving lives. I am excited to help lead this next chapter of growth as we expand biopharma partnerships, advance personalized medicine and bring life-changing therapies to patients faster and more effectively.”

Prior to MD Anderson, Dr. Prat held various leadership roles at Alere Inc. and its predecessors, now part of Abbott Laboratories. Earlier in his career, he served as a management consultant at McKinsey & Co.

Dr. Prat earned a PhD in Organic Chemistry from UCLA and a JD from the University of San Diego School of Law.

About BostonGene Corporation

BostonGene is a biotechnology company specializing in advanced computational biology and precision medicine. Founded in 2015, BostonGene has consistently pushed the boundaries of innovation to improve patient care and accelerate drug development. Our AI-powered multiomics platform decodes cancer patients' molecular profiles, including their immune system and tumor microenvironment, to uncover key disease drivers, identify novel drug targets and recommend the most effective treatments. With advanced bioanalytics, an indication-specific cancer library and a next-generation CLIA-certified, CAP-accredited high-complexity laboratory, we deliver precise, clinically validated insights that drive precision medicine and advance oncology research. For more information, visit www.BostonGene.com.

"As the industry increasingly focuses on personalized medicine and more strategic R&D investment, BostonGene is uniquely positioned to deliver real-world impact and drive meaningful transformation across healthcare and biopharma while saving lives."

Contacts

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.